Amsbio heparan sulfate monoclonal antibodies

Amsbio is a supplier of high-quality heparan sulfate (HS) monoclonal antibodies for use in brain and neurodegenerative research. In a recent study from Stanford University, published in the journal Nature, these antibodies have been used to reveal a key role for endothelial glycocalyx degradation in aging and neurodegenerative disease.

Heparan sulfate is a highly sulphated polysaccharide, synthesised as the glycosaminoglycan component of heparan sulfate proteoglycans (HSPGs). Due to its non-immunogenic nature, developing effective antibodies against HS has long been a challenge. Amsbio has overcome these limitations by offering a range of hybridoma-derived anti-HS antibodies including clones 10E4, 3G10 and JM403, which serve as critical molecular tools and biomarkers in brain research to map, visualise and analyse complex glycosaminoglycan patterns.

In the study, researchers used HS antibodies to help identify brain endothelial glycocalyx dysregulation as a molecular mechanism that contributes to blood–brain barrier dysfunction in aging and neurodegenerative diseases. The results demonstrate that restoring the brain endothelial glycocalyx may be an effective therapeutic route to combat blood–brain barrier breakdown in age-related central nervous system diseases.

HS antibodies from Amsbio are widely used by brain research groups around the world because of their high sensitivity, specificity and affinity to target antigens, plus they work across many model species. The company’s HS antibodies are rigorously validated to detect and quantify cell surface HS, providing correct data for diverse applications from investigating viral infections to exploring cancer and immunological disorders.